Andrew Armstrong
Dr. Armstrong earned a BS in Biomedical Engineering from Duke University, an MD degree from the University of Virginia and an MS in Clinical Investigation from Johns Hopkins University. He...Read More
Vivek Arora
Preclinical assessment of mechanisms of resistance to hormone therapy in prostate cancer has led to the discovery and development of a new medicine, named ARN-509. Dr. Arora has shown that...Read More
Jennifer Bishop
Approximately 25% of patients who fail Xtandi and Zytiga present with a lethal form of prostate cancer named neuroendocrine prostate cancer (NEPC). Features of NEPC include changes in hormonal sensitivity,...Read More
Irfan Asangani
The organization of DNA into super-structures is an ordered and normal process of cell growth that is dysregulated in cancer. Chemical modifications of DNA have been identified by Dr. Irfan...Read More
Charles Chan
Engraftment of prostate cancer in bone heralds a lethal form of the disease. New targets are needed for the treatment of prostate cancer in bone and to prevent bone localization...Read More
Chia-Yi Chu
An unmet medical need is the control of metastases of prostate cancer that cause the lethal form of this disease. Dr. Chu has discovered metastasis-initiating prostate cancer cells that circulate...Read More
Michael Evans
Molecular imaging of prostate cancer to determine sites of metastasis in recurrent patients is an unmet medical need. Dr. Evans is exploiting the activation of two cancer-causing genes (MYCand PI3K)...Read More
